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STAT3 transcription factor is persistently activated in
cancer cells and in diverse tumor-associated immune cells
being an important oncogene and an essential immune
checkpoint regulator. It is a highly desirable but challen-
ging therapeutic target for pharmacological intervention.
We previously demonstrated that ligand for the intracellu-
lar receptor TLR9 (CpG ODN) allows for the uptake and
cytoplasmic delivery of siRNA into specific target cells
[1-3]. Now, we used this approach to deliver decoy oligo-
deoxynucleotides (dODNs) to prevent STAT3 DNA bind-
ing and transcriptional activation in variety of mouse and
human target cells. These include immune cells (dendritic
cells, B cells and MDSCs) and certain types of cancer cells,
such as acute myeloid leukemia (AML) and B cell
lymphoma. After uptake, CpG-STAT3dODN molecules
bind and sequester activated STAT3 proteins, thereby
inhibiting their transcriptional activity. CpG-STAT3dODN
induced apoptosis in STAT3-dependent cancer cells
without affecting the viability of immune cells. In addition,
the concomitant STAT3-blocking/TLR9-triggering
augmented immunogenicity of patients’ derived AML
cells. CpG-STAT3dODN treatment reduced expression of
immunosuppressive enzyme, arginase-1, in leukemic cells
while upregulating levels of HLA-DR and costimulatory
molecules and partly restoring proliferation of co-cultured
autologous T cells. The chemically modified CpG-STAT3-
dODNs have improved resistance to serum degradation.
As shown by our studies using disseminated human
MV4-11 AML, repeated i.v. injections of CpG-STAT3-
dODN reduced levels of activated STAT3 in target cells
with ED50 ~2.5 mg/kg and within two weeks resulted in
AML regression. To assess the combined antitumor effect
of STAT3-blocking/TLR9-triggering in immunocompe-
tent host, we used syngeneic Cbfb/MYH11 AML. The i.v.
administration of CpG-STAT3dODN over two weeks
resulted in long-term survival of the majority of mice.
These potent antitumor effects resulted from the increased
immunogenicity of leukemic cells rather than host anti-
gen-presenting cells as suggested by the comparable extent
of tumor regression in wild-type and TLR9-deficient mice.
These finding support further development of CpG-
STAT3dODN strategy for treatment of AML and poten-
tially B cell lymphoma.
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